2025 has already begun with drama in the U.S., as Los Angeles recovers from deadly wildfires and Donald Trump is sworn in for his second presidency. And so it was that the mood going into the annual JP Morgan Healthcare Conference was clouded by uncertainty. With its timing in January, JPM is often seen as […]
225Ac-SSO110 (satoreotide) is a first in class Actinium-labelled SSTR2 receptor antagonist Phase I/II SANTANA-225 study on track to enrol patients in Q1 2025 Berlin, Germany, 14 January 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the US Food and Drug […]
Berlin, Germany / Garching / Munich, January 13, 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of a supply agreement for non-carrier-added (n.c.a.) Actinium-225 (Ac-225) to support the development […]
Berlin, Germany, 10 January 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced the appointment of David Schilansky as Chief Financial Officer with immediate effect, taking over from Rainer Sturm, who will ensure a smooth transition. David has more than 25 years […]
Amsterdam, The Netherlands, Basel, Switzerland and Ingelheim, Germany, (9 January 2025) — Boehringer Ingelheim and Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates (ADCs), today announced that Boehringer has licensed Synaffix’s ADC technology. This new partnership significantly bolsters Boehringer’s ADC portfolio, driven […]
